Zeo ScientifiX, Inc. Q2 2026 Financial Report: Key Highlights and Investor Insights
Summary of Results for the Quarter Ended April 30, 2026
Zeo ScientifiX, Inc. has released its financial results for the quarter ended April 30, 2026. The company, a Nevada corporation, filed its Form 10-Q, providing unaudited condensed consolidated financial statements. Below are the most important highlights and events that investors and shareholders should note.
Key Financial Highlights
- Share Structure: As of April 30, 2026, the company had 7,837,441 shares of common stock outstanding, with a par value of \$0.001 per share. During the quarter, 487,500 common shares were issued through sales, and 100,000 shares were issued as compensation.
- Stockholders’ Equity: As of April 30, 2026, stockholders’ equity stood at \$712,000, a significant decrease from \$1,423,000 as of October 31, 2025. This reflects ongoing net losses and other factors affecting equity.
- Net Loss: For the six months ended April 30, 2026, the company reported a net loss of \$2,634,000 (compared to \$1,391,000 for the three months ended April 30, 2026). The net loss per share (basic and diluted) was \$0.14, down from \$0.42 for the same period the previous year, reflecting ongoing challenges in achieving profitability.
- Revenue/Deferred Revenue: Deferred revenue as of April 30, 2026, was \$671,000, indicating ongoing prepayments or contractual obligations yet to be fulfilled.
- Obligation to Repurchase Shares: The company reported an obligation to repurchase shares of \$17,000 as of April 30, 2026, down from \$19,000 as of October 31, 2025.
- Cash Flows and Liquidity: Net cash provided by investing activities was \$298,000 for the six months ended April 30, 2026, mainly due to proceeds from the sale of Exotropin interests (\$376,000). The company raised \$1,950,000 through the issuance of common stock.
Significant Transactions and Price-Sensitive Information
- Sale of Exotropin Interests: The company recognized a gain of \$390,000 from the sale of Exotropin interests and received \$376,000 in proceeds. This transaction is a one-off and brings cash into the company but also means the loss of future income from these assets.
- Stock-Based Compensation: Zeo ScientifiX, Inc. recorded \$2,187,000 in stock-based compensation for the six months ended April 30, 2026. This is a substantial non-cash expense and may dilute shareholders.
- Increase in Shares Outstanding: The company increased its common shares outstanding by over 1.0 million since last year, mainly due to share-based payments and new equity issuances. This dilution could impact existing shareholders’ value.
- Impairment and Other Expenses: The company recorded impairments and changes in obligations to repurchase shares totaling \$2,000, and interest expenses of \$20,000.
- Going Concern: The company’s continued net losses, low stockholders’ equity, and reliance on new equity issuances for cash flow highlight ongoing risks regarding its ability to continue as a going concern.
Regulatory and Compliance Notes
- The company is a non-accelerated filer and qualifies as a smaller reporting company. It is not an emerging growth company or shell company.
- Zeo ScientifiX, Inc. has no securities listed on a national exchange. Its common stock is registered under Section 12(g) of the Securities Exchange Act.
- The company is current with its SEC filing obligations and has submitted all required interactive data files.
Forward-Looking Statements and Risks
The company’s report contains forward-looking statements. Actual results may differ materially due to various risks and uncertainties, including but not limited to market conditions, operational risks, and the ability to raise additional capital.
Potential Price-Sensitive and Shareholder-Relevant Items
- Share Dilution: The significant issuance of new shares (over 1 million shares in the past year for compensation and capital raising) is dilutive and may weigh on the share price.
- Ongoing Losses: The company continues to incur substantial losses, and its ability to achieve profitability remains uncertain.
- Asset Sale: The gain and cash inflow from the sale of Exotropin interests are positive for liquidity but may remove a source of future earnings.
- Reliance on Equity Financing: The company’s operations are being funded primarily through the sale of common stock, which is not sustainable long-term without improvements in profitability.
- Stock-Based Compensation: High levels of stock-based compensation indicate significant dilution risk for existing shareholders.
Conclusion
Zeo ScientifiX, Inc.’s Q2 2026 results highlight ongoing challenges regarding profitability and liquidity. The company is dependent on asset sales and equity financings, and continues to issue substantial shares for compensation and funding. While the cash inflow from asset sales and capital raising provides short-term relief, dilution and persistent losses are key concerns for shareholders. Any improvement in operating performance or successful new capital raising could be price-sensitive, but further dilution or operational setbacks may negatively impact the share price.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult with their financial advisors before making any investment decisions.
